Zymeworks, Inc. (ZYME)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$29.19-2.37%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ZYME
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 2.8% |
| Our one-year growth estimate | diamond | -60.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 62.8 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
ZYME — earnings miss
Dated 2026-08-06
RESULTS OF OPERATIONS AND FINANCIAL CONDITION On August 6, 2026, Zymeworks Inc. (the “Company”) issued a press release announcing its financial results for the three months ended June 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K (this “Form 8-K”).
Why it matters: Reducing expenses is key for improving cash flow and financial health. A successful cut would show management's commitment to cost control.
Supportive ifOperating expenses decrease by 10% or more in Q2 2026 compared to Q1 2026.
Worry ifOperating costs stay the same or go up in Q2 2026 compared to Q1 2026.
Why it matters: A partnership could provide needed capital support and enhance growth prospects. It would show that the company is actively seeking ways to strengthen its position.
Supportive ifA new partnership with financial support will be announced by the end of Q3 2026.
Worry ifNo partnership announcements by the end of Q3 2026.
Why it matters: Cutting expenses is important for better financial health. Progress may mean better results.
Supportive ifOperating costs were under $136 million for Q2 2026.
Worry ifOperating costs were over $136 million for Q2 2026.
Why it matters: If healthcare sector revenue growth speeds up, it may help Zymeworks. The company is struggling in a maturing sector.
Supportive ifHealthcare sector revenue growth shows a rise back toward 10% or higher.
Worry ifHealthcare sector revenue growth continues to slow or stays below 10%.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$197 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $402 loss on $10,000 · 4.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,363 loss on $10,000 · 23.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Cutting operating costs is important for better financial health. Not meeting goals may show bigger problems.
Worry ifOperating costs are at least 15% lower than last year's $170.5 million.
Less concerning ifOperating costs stay the same or go up compared to last year.
Why it matters: Updates on the program will show how much management trusts the stock.
Watch forManagement will use more of the $125 million share buyback program.
Also watch forManagement stops or cuts back the share buyback program.
Why it matters: Ongoing buybacks show management believes in the company's value. This can help the stock price.
Supportive ifZymeworks announces more use of the $125 million share buyback plan.
Worry ifZymeworks stops or cuts back the share buyback plan.
Why it matters: Lower expenses could help financial health and make investors happier.
Supportive ifGross operating expenses in 2026 are at least 20% lower than in 2025.
Worry ifGross operating expenses do not drop as expected.
Why it matters: New partnerships or acquisitions can strengthen the company's capital position. This is key for future growth.
Supportive ifThere is a new partnership or purchase. It helps with money and resources.
Worry ifNo new partnerships or acquisitions announced by the end of 2026.
Why it matters: Closing the acquisition could enhance Zymeworks' cash flow and diversify its revenue base. This is crucial for long-term growth.
Supportive ifThe Theravance Biopharma deal closes in the second half of 2026.
Worry ifThe deal does not close on time or has big delays.
Why it matters: Results may show zanidatamab works for GEA. This could affect sales and investor trust.
Watch forTop results from the second survival analysis come out in Q3 2026.
Also watch forResults show no big gain in overall survival over current treatments.